medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2016, Number 4

<< Back Next >>

Rev Invest Clin 2016; 68 (4)

Estimation of the Cost-Effectiveness of Breast Cancer Screening Using Mammography in Mexico Through a Simulation

Ulloa-Pérez E, Mohar-Betancourt A, Reynoso-Noverón N

Language: English
References: 26
Page: 184-191
PDF size: 88.93 Kb.


ABSTRACT

Background: Currently, breast cancer is the most prevalent tumor among Mexican women. Screening methods such as mammography could potentially reduce the health and economic burden of breast cancer; however, its risk-benefit balance is still unclear. Objective: To estimate the cost-effectiveness of different breast cancer screening programs using mammography in Mexico and to contribute to the decision-making process on this preventive measure. Methods: A simulation study was performed using population data and incidence rates. Several screening programs were assessed using the cost-effectiveness methodology recommended by the World Health Organization. Results: The feasible recommended screening program has an examination schedule periodicity of every three years, with a population coverage of 0, 15, 18, 20, 25, 20, 18, and 0% for the age groups of 25-40, 40-45, 45-50, 50-55, 55-60, 60-65, 65-70, and 70-75 years, respectively. Conclusions: Given the present coverage in Mexico, it is necessary to optimize our resource allocation to improve the country’s breast cancer prevention policy.


REFERENCES

  1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr [Accessed 16 December 2015].

  2. Anderson BO, Cazap E, El Saghir NS, et al. Optimisation of breast cancer management in low-resource and middle-resource countries: executive summary of the Breast Health Global Initiative consensus, 2010. Lancet Oncol. 2011;12:387-98.

  3. Gutiérrez JP, Rivera-Dommarco J, Shamah-Levy T, et al. Encuesta Nacional de Salud y Nutrición 2012. Resultados Nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública (MX), 2012.

  4. Ulloa, E. Github. 2015 Reproducibility Cost Effectiveness. Available at: https://github.com/ernesto-up/Reproducibility-Cost- Effectiveness

  5. Unger-Saldaña K, Miranda A, Zarco-Espinosa G, Mainero-Ratchelous F, Bargallo-Rocha E, Lázaro-León JM. Health system delay and its effect on clinical stage of breast cancer: Multicenter study. Cancer. 2015;121:2198-206.

  6. Tan-Torres Edejer T, Baltussen R, Adam T, et al. WHO Guide to Cost-Effectiveness Analysis. WHO, Geneva; 2003

  7. Secretaría de Gobernación. Projections of the population of Mexico from 2010 to 2050. Methodological document. Mexico, 2012. Available at: http://www.conapo.gob.mx/work/models/ CONAPO/Proyecciones/Documento_Metodologico/HTML/ files/assets/common/downloads/publication.pdf [Accessed 22 July 2015].

  8. Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-45.

  9. Instituto Nacional de Estadística y Geografía. Mujeres y Hombres en México 2013. México: INEGI Available at: http://www. inegi.org.mx/prod_serv/contenidos/espanol/bvinegi/productos/ integracion/sociodemografico/mujeresyhombres/2013/ Myh_2013.pdf [Accessed 21 November 2015].

  10. Duffy SW, Gabe R. What should the detection rates of cancers be in breast screening programmes? Br J Cancer. 2005;92:597-600.

  11. Tabár L, Vitak B, Chen HH, et al. The Swedish Two-Country Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am. 2000; 38:625-51.

  12. Ohta K, Kasahara Y, Tanaka F, Maeda H. Is clinical breast examination effective in Japan? Consideration from the age-specific performance of breast cancer screening combining mammography with clinical breast examination. Breast Cancer. 2016;23:183-9.

  13. Xie Y. knitr: A general-purpose package for dynamic report generation in R, R package version 1.10.5; 2015. Available at: http://yihui.name/knitr/ [Accessed 18 November 2015].

  14. Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, et al. Calculating disability-adjusted life years to quantify burden of disease. Int J Public Health. 2014;59:565-9.

  15. Kruijshaar ME, Barendregt JJ; European Disability Weights Group. The breast cancer related burden of morbidity and mortality in six European countries: The European Disability Weights project. Eur J Public Health. 2004;14:141-6.

  16. World Health Organization. Global Burden of Disease 2004 update: Disability weights for diseases and conditions. Geneva: WHO 2004. Available at: http://www.who.int/healthinfo/global_ burden_disease/GBD2004_DisabilityWeights.pdf [Accessed 21 November 2015].

  17. Comisión Nacional de Protección Social en Salud. Informe del Resultado de la Fiscalización Superior de la Cuenta Pública. 2012. Available at: http://www.asf.gob.mx/Trans/Informes/ IR2012i/Documentos/Auditorias/2012_0288_a.pdf [Accessed 30 July 2015].

  18. The World Bank. GDP per capita. Available at: http://data. worldbank.org/indicator/NY.GDP.PCAP.CD [Accessed 30 September 2015].

  19. Taghipour S, Banjevic D, Miller AB, Montgomery N, Jardine AK, Harvey BJ. Parameter estimates for invasive breast cancer progression in the Canadian National Breast Screening Study. Br J Cancer. 2013;108:542-8.

  20. Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries. Cancer. 2008;113:2221-43.

  21. Secretaría de Salud. Norma Oficial Mexicana NOM-041-SSA2- 2002, para la Prevención, Diagnóstico, Tratamiento, Control y Vigilancia Epidemiológica del Cáncer de Mama. Available at: http://www.salud.gob.mx/unidades/cdi/nom/041ssa202.html [Accessed 30 July 2015].

  22. National Cancer Institute. International Cancer Screening Network. Aug 2015. Available at: http://healthcaredelivery.cancer. gov/icsn/breast/screening.html [Accessed 24 April 2015].

  23. Zelle SG, Vidaurre T, Abugattas JE, et al. Cost-effectiveness analysis of breast cancer control interventions in Peru. PLoS One. 2013;8:e82575.

  24. World Health Organization. Breast Cancer Screening. International Agency for Research on Cancer. Lyon: IARC Press; 2002.

  25. Valencia-Mendoza A, Sánchez-González G, Bautista-Arredondo S, Torres Mejía G, Bertozzi SM. [Cost-effectiveness of breast cancer screening policies in Mexico]. Salud Publica Mex. 2009; 51(Suppl 2):296-304.

  26. Niëns LM, Zelle SG, Gutiérrez-Delgado C, et al. Cost-effectiveness of breast cancer control strategies in Central America: the cases of Costa Rica and Mexico. Plos One. 2014;9:e95836.




2020     |     www.medigraphic.com